Member Info for BuenaVista

Monday RNS - FDA approve fortnightly Phase 1a study

Tuesday RNS - Phase 1a data release notification

Wednesday RNS - Completion of C7 with no MTD

Thursday RNS - Receipt of milestone payment

No Friday RNS - Only losers issue news on a Friday

Not saying which week, mind.

Derek's worried about his investment and doesn't want Toulouse it.

They've mixed up their μMs and their mMs and patients have been receiving homeopathic concentrations. It'll all have to be done again.

LDA and Derek, help is available. Speak with someone today: 116 123

Derek's been LFT in 2021

12 more sleeps 🥱🛌🏼💤⏰

"And why isn't it re-advertised?" They will have likely had other possible candidates in mind when the advert was placed and have all the respondents to that advert anyway to look through. Expect whoever they choose, or have already chosen, will need to give some months' notice.

It may be stating the obvious but there will have been a LOT more information given out to the TG group than appeared in that approved report.

Stefan A for Tx, Cystatin A for Dx. (Or the other way round🤔)

The good news being that the train is full of gold?

Would that truly affect the company's prospects though?

I can see how it would affect the SP, driving it lower, but would that be a bad thing for LTHs given the chance to buy more shares at a lower price?

So it was RAH! RAH! RAH!'s turn to play with the magic calculator last night.🥱

Well we're all just overthinking Ambiguous Smith.

You guys!

"and it will be designed to be a registrational study in the US” means a registrational study to get approval in the US from the FDA.

You'll be getting canteen jobs in Scale Space to read the tea leaves in the bottom of Alan's cup next.

@Wyndrum: Frankly, I'm not surprised. Formulated AVA6000 will be in very short supply and expensive to produce at the moment. There is also the reputational risk to the company of its use outside their control. Finally, if it was priced at an 'affordable' cost, then everyone would want to have it and ...you do understand about supply and demand don't you?

Pfft! Everyone knows that the chance of getting the desired RNS is 50/50 every day.

I saw that as well as I follow Aptamer news. Far too speculative and hypothetical for Tx I think but Optimers for Dx could be seen as another string for Avacta's bow as Aptamer did gain some traction by way of deals with pharma companies.

Have you ever heard the proverb "Don't count your chickens before they hatch"?

😂 finer points

This describes the finger points of the difference between unlicensed and off-label.

https://www.ouh.nhs.uk/patient-guide/leaflets/files/72458unlicenced.pdf

This is also called off-label prescribing and is, as you noted, the responsibility of the physician. Exact requirements would be dependent upon the regulatory authority of the country involved - as long as that country's regulatory authority allows off-label prescribing.

https://www.google.com/search?q=off-label+prescribing